Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical
- PDF / 1,601,392 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 27 Downloads / 177 Views
ORIGINAL RESEARCH
Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials? Björn Koneswarakantha1 · Timothé Ménard1 · Donato Rolo2 · Yves Barmaz1 · Rich Bowling3 Received: 17 December 2019 / Accepted: 13 March 2020 / Published online: 30 March 2020 © The Author(s) 2020
Abstract Background The increasing number of clinical trials and their complexity make it challenging to detect and identify clinical quality issues timely. Despite extensive sponsor audit programs and monitoring activities, issues related to data integrity, safety, sponsor oversight and patient consent have recurring audit and inspection findings. Recent developments in data management and IT systems allow statistical modeling to provide insights to clinical Quality Assurance (QA) professionals to help mitigate some of the key clinical quality issues more holistically and efficiently. Methods We used findings from a curated data set from Roche/Genentech operational and quality assurance study data, covering a span of 8 years (2011–2018) and grouped them into 5 clinical impact factor categories, for which we modeled the risk with a logistic regression using hand crafted features. Results We were able to train 5 interpretable, cross-validated models with several distinguished risk factors, many of which confirmed field observations of our quality professionals. Our models were able to reliably predict a decrease in risk by 12–44%, with 2–8 coefficients each, despite a low signal-to-noise ratio in our data set. Conclusion We proposed a modeling strategy that could provide insights to clinical QA professionals to help them mitigate key clinical quality issues (e.g., safety, consent, data integrity) in a more sustained data-driven way, thus turning the traditional reactive approach to a more proactive monitoring and alerting approach. Also, we are calling for cross-sponsors collaborations and data sharing to improve and further validate the use of statistical models in clinical QA. Keywords Quality assurance · Clinical trial · Advanced analytics · Statistical modeling · Good clinical practice (GCP) · Audit
Background Compliance with the fundamental principles of good clinical practice (GCP) ensures the rights, safety and well-being of research subjects and ensures the integrity of clinical research data. Trial sponsors are required by the International Conference on Harmonization (ICH) guidelines to implement and maintain Quality assurance (QA) and quality control systems to achieve these objectives [1].
* Timothé Ménard [email protected] 1
F. Hoffmann‑La Roche, Basel, Switzerland
2
Roche Products Ltd, Welwyn Garden City, UK
3
Genentech Inc., A member of the Roche Group, South San Francisco, USA
Traditional clinical QA practices heavily rely on audits to detect sites or studies with quality issues [2]. Audit programs usually follow a risk-based approach hence all studies cannot be covered. Furthermore, audits often report on issues that have already occurr
Data Loading...
